新诊断前列腺癌的HIV阳性患者的临床管理与结局:单中心经验
Clinical management and outcomes of HIV-positive patients newly diagnosed with prostate cancer: a single institution experience.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-09-03
该单中心研究纳入52例新诊断前列腺癌的HIV感染者,按临床、病理及HIV特征分层分析无病生存期。结果显示,按前列腺癌治疗方式、CD4计数或HIV病毒载量分层,无病生存期均无差异。作者认为HIV感染者前列腺癌结局良好,与治疗方式无关。
要点
- 52例HIV感染合并前列腺癌患者纳入分析。
- 按治疗方式、CD4计数或HIV病毒载量分层,无病生存期无差异。
- 作者认为HIV感染者前列腺癌结局良好,与治疗方式无关。
核心结论
- HIV感染者的前列腺癌结局良好,与治疗方式无关。
研究设计与样本
- 单中心研究,52例HIV感染者诊断为前列腺癌,按临床、病理及HIV特征分层分析无病生存期。
主要发现
- 按前列腺癌治疗方式、CD4计数或HIV病毒载量分层,无病生存期均无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: 10-year outcomes in patients living with HIV who are diagnosed with prostate cancer are unknown. METHODS: 52 patients living with HIV were diagnosed with prostate cancer. Disease-free survival stratified by clinical, pathologic, and HIV characteristics were examined. RESULTS: No difference in disease-free survival was observed based on prostate cancer treatment modality, CD4 count, or HIV viral load. CONCLUSIONS: Prostate cancer outcomes in patients living with HIV are favorable irrespective of treatment modality.
来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。
引用
- Markowski MC, Pirsl F, Keruly JC, et al. Clinical management and outcomes of HIV-positive patients newly diagnosed with prostate cancer: a single institution experience. Prostate Cancer Prostatic Dis. 2022. PMID: 36057651. doi:10.1038/s41391-022-00586-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。